替米沙坦对肝纤维化大鼠肝组织病理学变化的影响

Study on pathologic changes of hepatic fibrosis by telmisartan in experimental rats

目的观察替米沙坦对四氯化碳(CCl4)诱导的大鼠实验性肝纤维化模型肝组织病理学变化的影响。方法 SD大鼠40只被随机分成正常对照组(12只)、模型组(12只)和替米沙坦防治组(16只)。在制备大鼠肝纤维化动物模型成功后,取肝、脾,常规进行组织病理学检查。结果模型组大鼠平均肝指数为4.85±0.42(P<0.05),正常对照组为2.92±0.41,而药物干预组为3.09±0.36;模型组大鼠肝炎症活动度平均计分为18.6±2.1(P<0.05),正常对照组为0.0±0.0,替米沙坦干预组为8.6±1.9;模型组大鼠肝纤维化计分平均为14.5±1.6,正常对照组为0.33±0.49,替米沙坦干预组为7.7±1.7(P<0.01)。结论替米沙坦可改善实验性纤维化大鼠肝组织病理学损伤。

Objective To investigate the effect of telmisartan on hepatic fibrosis induced by CCl4 in experimental rats.Methods Total 40 male SD rats were randomly divided into 3 groups,i.e,control（n=12）,model（n=12）and telmisartan groups（n=16）.The liver fibrotic model was induced by CCl4 and the liver pathological changes were observed.Results The liver index in model was 4.85±0.42,in control was 2.92±0.41 and in interventional group was 3.09±0.36（P〈0.05）;The HAI in model was 18.6±2.1,in normal was 0.0±0.0 and in telmisartan group was 8.6±1.9（P〈0.01）;the hepatic fibrosis scores in model was 14.5±1.6,in control was 0.33±0.49 and in telmisartan group was 7.7±1.7（P〈0.01）.Conclusions Telmisartan can improve the hepatic fibrosis in rats.